Target family: C1: Papain (type: enzyme)
Target: cathepsin K

Ligand: balicatib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.850000381469727 pIC50
Reference (Journal): Emerging targets in osteoporosis disease modification.
Published in: J Med Chem

Ligand: calpeptin (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.960000038146973 pIC50
Reference (Journal): Design of small molecule ketoamide-based inhibitors of cathepsin K.
Published in: Bioorg Med Chem Lett

Ligand: compound 1b [PMID: 16290936] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.739999771118164 pKi
Reference (Journal): Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors?
Published in: Bioorg Med Chem Lett

Ligand: compound 23 [PMID: 35944849] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.300000190734863 pIC50
Reference (Journal): Lead optimization of cathepsin K inhibitors for the treatment of Osteoarthritis.
Published in: Bioorg Med Chem Lett

Ligand: GC-376 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.590000152587891 pIC50
Reference (Journal): Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir.
Published in: ACS Pharmacol Transl Sci

Ligand: K777 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.400000095367432 pKi
Reference (Journal): A Clinical-Stage Cysteine Protease Inhibitor blocks SARS-CoV-2 Infection of Human and Monkey Cells.
Published in: ACS Chem Biol

Ligand: L873724 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9.699999809265137 pIC50
Reference (Journal): Pharmacological inhibitors to identify roles of cathepsin K in cell-based studies: a comparison of available tools.
Published in: Biol Chem

Ligand: odanacatib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9.699999809265137 pIC50
Reference (Journal): The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
Published in: Bioorg Med Chem Lett

Ligand: relacatib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9.390000343322754 pKi
Reference (Journal): Emerging targets in osteoporosis disease modification.
Published in: J Med Chem

Ligand: UAWJ9-36-3 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.380000114440918 pIC50
Reference (Journal): Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir.
Published in: ACS Pharmacol Transl Sci